Avanos Medical (AVNS)
(Delayed Data from NYSE)
$23.02 USD
+0.53 (2.36%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $23.03 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
A Value D Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.02 USD
+0.53 (2.36%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $23.03 +0.01 (0.04%) 7:58 PM ET
2-Buy of 5 2
A Value D Growth D Momentum B VGM
Zacks News
PerkinElmer's (PKI) Latest Launch to Boost Research Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to provide increased assay flexibility to researchers.
Reasons to Add Quest Diagnostics (DGX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Quest Diagnostics (DGX) on its accelerated growth strategy and improvements in base volumes.
BD's (BDX) New FDA Approval to Improve Cervical Cancer Testing
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of cervical cancer.
What Makes Avanos Medical (AVNS) a New Buy Stock
by Zacks Equity Research
Avanos Medical (AVNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Avanos (AVNS) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Avanos' (AVNS) fourth-quarter 2022 results reflect strength in both segments.
Avanos Medical (AVNS) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 25% and 1.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2023
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks - DYNT, INGN, AVNS - which are expected to provide long-term gains.
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Avanos Medical (AVNS) Up 21% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Avanos (AVNS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Avanos' (AVNS) third-quarter 2022 results reflect strength in the Pain Management segment.
Avanos Medical (AVNS) Tops Q3 Earnings Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 5.56% and 1.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
LivaNova (LIVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 5th
by Zacks Equity Research
AVNS, NKE and PLAB have been added to the Zacks Rank #5 (Strong Sell) List on October 5, 2022.
New Strong Sell Stocks for September 28th
by Zacks Equity Research
AVNS, ARCE and DCO have been added to the Zacks Rank #5 (Strong Sell) List on September 28, 2022.
Strength Seen in Treace Medical Concepts (TMCI): Can Its 8.4% Jump Turn into More Strength?
by Zacks Equity Research
Treace Medical Concepts (TMCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Avanos Medical (AVNS) Down 14% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos (AVNS) Q2 Earnings Top Estimates, FY22 View Lowered
by Zacks Equity Research
Avanos's (AVNS) second-quarter 2022 results reflect strength in the Pain Management segment.
Avanos Medical (AVNS) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 5.13% and 2.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Integer (ITGR) Q2 Earnings Miss Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of -11.86% and 1.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Inari Medical, Inc. (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos Medical (AVNS) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What to Expect From Molina Healthcare's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results are likely to reflect benefits from higher premiums stemming from Medicaid and Medicare businesses, partly offset by elevated medical care costs.
Can Avanos Medical (AVNS) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Avanos Medical (AVNS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.